H D I N S I G H T S
HD Insights, Vol. 10 9
Copyright © Huntington Study Group 2015. All rights reserved.
Clinical Trials Update
SPONSOR STUDY
NAME/
IDENTIFIER
STUDY
AGENT
PHASE
PRINCIPAL
INVESTIGATOR,
CONTACT
DESIGN TRIAL
LENGTH
SITES STATUS
Charité University
ETON-Study
Epigallocatechin
gallate
II
Josef Priller, MD
+49 (0)30 450 617209
Randomized double-blind study testing the
efficacy and tolerability of (2)-
epigallocatechin-3-gallate (EGCG) in changing
cognitive function in HD patients
1 year
4 total -
Germany
Enrollment
complete,
study
ongoing
Charité
University
Action-HD
Bupropion
II
Josef Priller, MD
+49 (0)30 450 617209
Randomized double-blind study testing the
efficacy and tolerability of bupropion in
changing apathy in patients with HD
10 weeks
3 total -
Germany
Study
complete
Ipsen
NCT02231580
BN82451B
II
Bruno Padrazzi,
M.D.
clinical.trials@ipsen.
com
Dose escalation, proof of concept study to
investigate the safety and tolerability, the
pharmacokinetic and the pharmacodynamic
properties of twice daily BN82451B for four
weeks in male patients with HD
28 days
1 total -
Germany
Currently
enrolling
Omeros
Corporation
NCT02074410
OMS643762
II
Albert Yu, MD
206-676-5000
Randomized, double-blind, placebo-controlled,
sequential cohort study to evaluate safety and
efficacy of OMS643762 in subjects with HD
28 days
4 total -
United States
Trial
suspended
Prana
Biotechnology
REACH2HD
PBT2
II
Ray Dorsey, MD
Randomized double-blind safety and tolerability
study of PBT2 of individuals with mild to
moderate HD
6 months
20 total -
Australia
and United
States
Results
published
Pfizer
NCT01806896
PF-0254920
II
Pfizer CT.gov Call
Center,
800-718-1021
Randomized, double-blind, placebo-controlled
study to evaluate the safety, tolerability and
brain cortico-striatal function of 2 doses of
PF-02545920 in individuals with early HD
28 days
Paris,
France
Currently
enrolling
Pfizer
NCT02197130
PF-0254920
II
Pfizer CT.gov Call
Center,
800-718-1021
Randomized, double-blind, placebo-controlled
proof of concept study of the efficacy and safety
of PF-02545920 in HD
26 weeks
23 total -
Europe and
United
States
Currently
enrolling
Teva
Pharmaceutical
Industries
PRIDE-HD
Pridopidine
II
Teva US Medical
Information
800-896-5855
Randomized, double-blind, placebo-controlled
study of safety and efficacy of pridopidine 45
mg, 67.5 mg, 90 mg, and 112.5 mg BID versus
placebo for symptomatic treatment in patients
with HD
26 weeks
57 total -
worldwide
Currently
enrolling
Teva
Pharmaceutical
Industries
OPEN-HART
Pridopidine
II
Karl Kieburtz, MD,
MPH
Open-label, single group assignment study to
assess the long-term safety of 45 mg of
pridopidine in HD participants
2 years
22 total -
United
States and
Canada
Enrollment
complete,
study
ongoing
Teva
Pharmaceutical
Industries
LEGATO-HD
Laquinimod
II
Teva US Medical
Information
800-896-5855
Randomized, double-blind, placebo-controlled,
parallel-group study evaluating efficacy and
safety of Laquinimod (0.5, 1.0 and 1.5 mg/day)
in HD
12 months
46 total -
worldwide
Currently
enrolling
Raptor
Pharmaceuticals
CYST-HD
Cysteamine
bitartrate
delayed-release
capsules (RP103)
II/III
Christophe Verny,
MD
Double-blind, placebo-controlled study to be
followed by an open-label extension study
36 months
8 total -
France
Study
ongoing,
preliminary
results
released
National
Institute of
Neurological
Disorders and
Stroke
2CARE
Coenzyme Q10
III
Merit Cudkowicz,
MD, MSc
Randomized double-blind study to see whether
coenzyme Q10 is effective in slowing the
worsening of symptoms of HD
5 years
48 total -
United
States,
Canada,
Australia
Study
concluded for
futility
National Center
for
Complementary
and Alternative
Medicine
CREST-E
Creatine
III
Steven M Hersch,
MD, PhD
Randomized double-blind study to test whether
high-dose creatine can slow the progressive
functional decline that occurs in adults with
early clinical features of HD
3 years
52 total -
United
States,
Canada,
Australia,
New
Zealand
Study
concluded for
futility
To update or add a clinical trial, please e-mail editor@hdinsights.org.
Sources: www.clinicaltrials.gov and apps.who.int/trialsearch/
H D I N S I G H T S
